MDX 11
Alternative Names: Anti-AML/SCCL-trigger monoclonal antibody; Anti-CD15 monoclonal antibody PM-81; Monoclonal antibody PM-81Latest Information Update: 20 Aug 2002
At a glance
- Originator Medarex
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 20 Aug 2002 Discontinued - Phase-II for Acute myeloid leukaemia in USA (unspecified route)
- 20 Oct 1997 Phase-II clinical trials for Acute myeloid leukaemia in USA (Unknown route)
- 01 Oct 1996 A study has been added to the therapeutic trials, adverse effects, immunogenicity and pharmacokinetics sections